Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4646947
Max Phase: Preclinical
Molecular Formula: C79H116N20O20S
Molecular Weight: 1697.98
Molecule Type: Unknown
Associated Items:
ID: ALA4646947
Max Phase: Preclinical
Molecular Formula: C79H116N20O20S
Molecular Weight: 1697.98
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(N)=O
Standard InChI: InChI=1S/C79H116N20O20S/c1-9-42(6)65(78(118)97-53(32-45-22-14-11-15-23-45)72(112)92-55(34-59(81)101)67(107)87-39-62(84)104)98-69(109)50(27-29-120-8)89-73(113)54(33-46-38-86-48-25-17-16-24-47(46)48)91-68(108)49(26-18-19-28-80)88-71(111)52(31-44-20-12-10-13-21-44)90-70(110)51(30-40(2)3)96-79(119)66(43(7)100)99-76(116)57(36-61(83)103)93-75(115)58(37-63(105)106)94-74(114)56(35-60(82)102)95-77(117)64(85)41(4)5/h10-17,20-25,38,40-43,49-58,64-66,86,100H,9,18-19,26-37,39,80,85H2,1-8H3,(H2,81,101)(H2,82,102)(H2,83,103)(H2,84,104)(H,87,107)(H,88,111)(H,89,113)(H,90,110)(H,91,108)(H,92,112)(H,93,115)(H,94,114)(H,95,117)(H,96,119)(H,97,118)(H,98,109)(H,99,116)(H,105,106)/t42-,43+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-,65-,66-/m0/s1
Standard InChI Key: CGRZGOOJGKLIRL-JCZFEVJLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1697.98 | Molecular Weight (Monoisotopic): 1696.8395 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Saitoh M, Takayama K, Hitachi K, Taguchi A, Taniguchi A, Tsuchida K, Hayashi Y.. (2020) Discovery of a follistatin-derived myostatin inhibitory peptide., 30 (3): [PMID:31874826] [10.1016/j.bmcl.2019.126892] |
Source(1):